中欧医疗健康增聘基金经理，继续看好创新药投资机会

Core Viewpoint - The appointment of Zhao Lei as a co-manager for the China Europe Medical Health fund alongside Ge Lan reflects a growing trend in the fund management industry towards team-based management to enhance research efficiency and operational stability [1][2][3]. Group 1: Fund Management Changes - On July 4, China Europe Medical Health announced the appointment of Zhao Lei as a co-manager, who will work alongside Ge Lan, while other products like China Europe Medical Innovation will continue to be managed solely by Ge Lan [1][3]. - Zhao Lei has over 8 years of experience in the pharmaceutical and biotechnology sector and has previously led a team that won the "Golden Bull Award" for best industry analysis team in 2020 [3]. - As of the end of Q1, the China Europe Medical Health fund had a total size of 31.179 billion yuan [3]. Group 2: Industry Trends - There has been a significant increase in the adoption of "co-management" among funds, with over 600 funds implementing this model in 2023 alone [2][7]. - The shift towards team-based management is supported by regulatory guidance aimed at enhancing the research and investment capabilities of fund managers [8][9]. - The China Securities Regulatory Commission has emphasized the need for fund managers to build integrated, team-based research systems to improve investment decision-making and risk management [8][9]. Group 3: Future Investment Outlook - Ge Lan remains optimistic about the future of the healthcare sector, particularly in areas such as innovative drugs, recovery in consumer healthcare, and domestic substitution in key industry segments [5]. - The demand for innovative drugs is expected to continue growing, supported by global collaborations and key clinical data disclosures [5]. - The consumer healthcare sector, including aesthetics and ophthalmology, is anticipated to benefit from increased health management awareness among residents, with demand expected to rise as the economy recovers [5].